###begin article-title 0
###xml 70 74 <span type="species:ncbi:10090">Mice</span>
Increased Expression of CCL2 in Insulin-Producing Cells of Transgenic Mice Promotes Mobilization of Myeloid Cells From the Bone Marrow, Marked Insulitis, and Diabetes
###end article-title 0
###begin p 1
###xml 38 58 38 58 <email xmlns:xlink="http://www.w3.org/1999/xlink">sergio.lira@mssm.edu</email>
###xml 83 107 83 107 <email xmlns:xlink="http://www.w3.org/1999/xlink">glaucia.furtado@mssm.edu</email>
Corresponding author: Sergio A. Lira, sergio.lira@mssm.edu, or Glaucia C. Furtado, glaucia.furtado@mssm.edu
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE-To define the mechanisms underlying the accumulation of monocytes/macrophages in the islets of Langerhans.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 187 202 <span type="species:ncbi:10090">transgenic mice</span>
RESEARCH DESIGN AND METHODS-We tested the hypothesis that macrophage accumulation into the islets is caused by overexpression of the chemokine CCL2. To test this hypothesis, we generated transgenic mice and evaluated the cellular composition of the islets by immunohistochemistry and flow cytometry. We determined serum levels of CCL2 by enzyme-linked immunosorbent assay, determined numbers of circulating monocytes, and tested whether CCL2 could mobilize monocytes from the bone marrow directly. We examined development of diabetes over time and tested whether CCL2 effects could be eliminated by deletion of its receptor, CCR2.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 156 171 <span type="species:ncbi:10090">transgenic mice</span>
###xml 356 360 <span type="species:ncbi:10090">Mice</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
RESULTS-Expression of CCL2 by beta-cells was associated with increased numbers of monocytes in circulation and accumulation of macrophages in the islets of transgenic mice. These changes were promoted by combined actions of CCL2 at the level of the bone marrow and the islets and were not seen in animals in which the CCL2 receptor (CCR2) was inactivated. Mice expressing higher levels of CCL2 in the islets developed diabetes spontaneously. The development of diabetes was correlated with the accumulation of large numbers of monocytes in the islets and did not depend on T- and B-cells. Diabetes could also be induced in normoglycemic mice expressing low levels of CCL2 by increasing the number of circulating myeloid cells.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-These results indicate that CCL2 promotes monocyte recruitment by acting both locally and remotely and that expression of CCL2 by insulin-producing cells can lead to insulitis and islet destruction.
###end p 6
###begin p 7
Published ahead of print at  on 15 July 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 32 36 32 36 <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" vol="57" page="2922" id="N0x19d2390N0x39dfba0" xlink:href="18971442" ext-link-type="pubmed">2922</related-article>
See accompanying commentary, p. 2922.
###end p 9
###begin p 10
###xml 190 191 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 192 193 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 366 367 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 432 433 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 612 613 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 737 738 731 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 992 993 978 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 1096 1097 1082 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 576 580 <span type="species:ncbi:10090">mice</span>
###xml 1086 1094 <span type="species:ncbi:9606">patients</span>
Type 1 diabetes is a chronic inflammatory disorder characterized by infiltration of the islets of Langerhans by mononuclear cells and autoimmune destruction of insulin-producing beta-cells (1,2). Several lines of evidence suggest that macrophages play a role in the development of diabetes. Macrophages are the first cells that appear within the islets of NOD mice (3) and are also implicated in late phases of disease development (4). Administration of clodronate-loaded liposomes, which leads to disappearance of macrophages from the endocrine pancreas and periphery of NOD mice, delays the onset of diabetes (5). Moreover, macrophage depletion inhibits the development of beta-cell-cytotoxic T-cells and prevents autoimmune diabetes (6). It has been suggested that the presentation of self-antigens to autoreactive T-cells by dendritic cells and macrophages recruited and activated by transgenic tumor necrosis factor-alpha (TNF-alpha) expression accounts for the development of diabetes (7). Macrophages and dendritic cells are found within islets from recent-onset type 1 diabetic patients (8).
###end p 10
###begin p 11
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 217 221 217 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 227 228 227 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 240 241 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 399 400 399 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 408 411 408 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 417 418 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 429 430 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
Tissue macrophages originate from monocytes produced in the bone marrow. Current studies suggest that bone marrow-derived monocytes give rise to two subsets of peripheral blood monocytes (9). One subset (GR-1-, CX3CR1high, CCR2-, and CCL62L- monocytes) gives origin to tissue macrophages (splenic macrophages, Kupffer cells, alveolar macrophages, microglia, and osteoclasts). The second subset (GR-1+, CX3CR1low, CCR2+, and CD62L+ monocytes) is preferentially recruited to inflamed tissues and gives rise to macrophages and dendritic cells. This inflammatory subset also expresses CD115 (granulocyte macrophage colony-stimulating factor receptor) and Ly6C (10,11).
###end p 11
###begin p 12
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 576 578 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 716 718 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 779 781 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 817 819 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 545 551 <span type="species:ncbi:10090">murine</span>
Several studies implicate the chemokine CCL2 in monocyte recruitment in vivo (12). CCL2 promotes recruitment of monocytes, macrophages, dendritic cells, and activated T-cells via its receptor, CCR2 (13). Numerous cell types, including fibroblasts, endothelial cells, epithelial cells, leukocytes, and smooth muscle cells express CCL2 in the presence of serum or specific stimuli (14,15). In addition to chemotaxis, CCL2 contributes to activation of monocytes and macrophages because CCL2 induces production of TNF-alpha and interleukin-1beta in murine peritoneal macrophages (16). Macrophage recruitment caused by CCL2 expression has been strongly linked to several inflammatory conditions, such as atherosclerosis (17), development of intimal hyperplasia after arterial injury (18), obesity, and insulin resistance (19).
###end p 12
###begin p 13
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 71 77 <span type="species:ncbi:10090">murine</span>
###xml 82 87 <span type="species:ncbi:9606">human</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
CCL2 expression has also been related to diabetes. Primary cultures of murine and human pancreatic islets express and secrete CCL2 (20). CCL2 expression has been detected in islets of NOD mice during cyclophosphamide treatment (21), and CCL2 expression parallels disease progression in NOD mice (22,23). Low-level secretion of CCL2 by islets before transplantation is associated with a higher rate of insulin independence, suggesting an important role for CCL2 in the clinical outcome of islet transplantation in patients with type 1 diabetes (24).
###end p 13
###begin p 14
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 387 389 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 142 157 <span type="species:ncbi:10090">transgenic mice</span>
Our laboratory and others have shown that CCL2 expression by insulin-producing cells induces the accumulation of macrophages in the islets of transgenic mice (25,26). We have also found that transgenic expression of CCL2 induces migration of dendritic cells to the islets and that the number of inflammatory cells recruited is dependent on the levels of CCL2 produced by the beta-cells (26). The mechanisms controlling accumulation of monocytes in nonlymphoid tissues in response to increased levels of CCL2 have not been examined. It is unclear whether the accumulation of monocytes in inflamed tissues in response to CCL2 reflects increased recruitment of circulating monocytes or monocyte precursors, changes in the number of circulating monocytes, or both. Finally, it is unclear whether changes in local levels of CCL2 may promote development of diabetes.
###end p 14
###begin p 15
Here, we show that transgenic expression of CCL2 by insulin-producing cells is associated with changes in the number of monocytes in circulation. The monocytes are mobilized from the bone marrow in a CCR2-dependent mechanism. We also found spontaneous development of diabetes in two of the four transgenic lines expressing the highest levels of CCL2 in the pancreas. The development of diabetes required the accumulation of a large number of monocytes in the islets and did not depend on T- or B-cells. Animals expressing low levels of CCL2 in the islets did not spontaneously develop diabetes but became diabetic if the number of circulating monocytes was increased. These results indicate that CCL2 promotes monocyte recruitment by acting both locally and remotely and that dysregulated expression of CCL2 by insulin-producing cells can lead to insulitis and islet destruction.
###end p 15
###begin title 16
RESEARCH DESIGN AND METHODS
###end title 16
###begin p 17
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 103 106 103 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 155 158 155 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 246 261 <span type="species:ncbi:10090">transgenic mice</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
RIPCCL2 mice were generated as described by Martin et al. (26) in B6D2 (C57BL/6 x DBA) background. CCR2-/- mice were described by Boring et al. (13). Rag-1-/- mice were obtained from The Jackson Laboratories (Bar Harbor, ME). In all experiments, transgenic mice were compared with their corresponding littermates. All mice were housed under specific pathogen-free conditions in individually ventilated cages at the Mount Sinai School of Medicine Animal Facility. All experiments were performed following institutional guidelines.
###end p 17
###begin title 18
Diabetes.
###end title 18
###begin p 19
The blood glucose was monitored weekly using a one-touch blood Ascensia Contour glucometer (Bayer, Elkhart, IN). Animals were considered diabetic when their blood glucose levels were >250 mg/dl in two consecutive daily measurements.
###end p 19
###begin title 20
Histology.
###end title 20
###begin p 21
###xml 739 749 <span type="species:ncbi:10141">guinea pig</span>
###xml 866 870 <span type="species:ncbi:9925">goat</span>
###xml 876 879 <span type="species:ncbi:10116">rat</span>
###xml 949 953 <span type="species:ncbi:9925">goat</span>
###xml 959 975 <span type="species:ncbi:10032">Armenian hamster</span>
###xml 1023 1033 <span type="species:ncbi:10141">guinea pig</span>
###xml 1061 1065 <span type="species:ncbi:9925">goat</span>
###xml 1071 1074 <span type="species:ncbi:10116">rat</span>
Tissues for light microscopic examination were fixed by immersion in 10% phosphate-buffered formalin and then processed for paraffin sections. Routinely, 5-mum sections were cut and stained with hematoxylin-eosin (H-E). For immunohistochemical staining, fresh frozen sections were first fixed with ice-cold acetone for 20 min, dried, and stored at -20degreesC. Slides were incubated for 1 h at room temperature with purified primary antibodies followed by incubation with the appropriate labeled secondary antibodies for 30 min. Primary antibodies used were anti-CD45 (550539), CD3 (550275), CD11c (550283), B220 (550286), and CD11b (553308) from BD Biosciences Pharmingen (San Diego, CA); F4/80 (MCAP497) from Serotec (Oxford, U.K.); and guinea pig polyclonal anti-insulin (A0564) from Dako (Carpentaria, CA). Secondary antibodies used were Alexa Fluor 488 and 594 goat anti-rat IgG (A-11006 and A-11007) from Molecular Probes (Eugene, OR) and Cy3 goat anti-Armenian hamster (127-165-160), fluorescein isothiocyanate anti-guinea pig IgG (706-095-148), and Cy5 goat anti-rat (112-175-167) from Jackson ImmunoResearch (West Grove, PA).
###end p 21
###begin p 22
###xml 79 80 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 583 588 <span type="species:ncbi:10090">mouse</span>
To determine the degree of islet infiltration in RIPCCL2 mice, groups of mice (n = 5) were analyzed at 4 weeks of age. The total number of islets was counted in each section (assessing 40-100 islets per animal), and semiquantitative analysis was performed on insulin/CD45-stained sections. Insulitis was scored as follows: 0, no lesions; 1, peri-insular leukocytic aggregates; 2, moderate insulitis with mononuclear cells infiltrating <50% of the islet architecture; and 3, severe insulitis with >50% of the islet tissue infiltrated by mononuclear cells. An insulitis score for each mouse was obtained by dividing the total score for each pancreas by the number of islets examined. Data are presented as mean insulitis score +/- SE for the indicated experimental group.
###end p 22
###begin title 23
In situ perfusion of femoral bone marrow.
###end title 23
###begin p 24
###xml 14 18 <span type="species:ncbi:10090">mice</span>
Female BALB/c mice were anesthetized with urethane (25% 0.2 ml i.p.), and the femoral artery and vein were exposed. The hind limb was isolated by occlusion of the external iliac artery, superficial epigastric, and muscular branch with 5/0 braided silk suture. Polyethylene cannulae (0.61-mm outer diameter; Portex, London) were immediately inserted into the femoral artery and vein and tied in place with 5/0 braided silk suture. Perfusion buffer (modified Krebs-Ringer bicarbonate buffer) at 37degreesC was infused (0.15 ml/min) via the arterial cannula and removed from the venous cannula using a Minipuls peristaltic pump (Anachem, Luton, U.K.). The hind limb was perfused for an initial 10 min to remove remaining blood from the vasculature and then perfused for a further 60 min with vehicle alone or 80 nmol/l CCL2 (250-10; Peprotech, London) infused over the first 20 min using an infusion/withdrawal pump (Harvard Instruments, Edenbridge, U.K.). Resulting perfusate was kept on ice.
###end p 24
###begin title 25
Intraperitoneal glucose tolerance test.
###end title 25
###begin p 26
###xml 333 337 <span type="species:ncbi:10090">mice</span>
After a 16-h fast, glucose (1.5 g/kg body wt in saline [0.9% NaCl]) was administered intraperitoneally. The blood glucose was monitored at 0, 30, 60, 120, and 240 min using a one-touch blood Ascensia Contour glucometer (Bayer). The intraperitoneal glucose tolerance test was performed on 8-week-old control and normoglycemic RIPCCL2 mice.
###end p 26
###begin title 27
Isolation of pancreatic islets of Langerhans.
###end title 27
###begin p 28
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
Islets of Langerhans were isolated as previously described (27). Briefly, the common bile duct was clamped distal to the pancreatic duct junction at its hepatic insertion. The proximal common bile duct was then cannulated using a 27-gauge needle, and the pancreas was infused by retrograde injection of 2 ml 1.0 mg/ml ice-cold collagenase solution (Sigma, St. Louis, MO) in Hanks' balanced salt solution (HBSS; Invitrogen, Carlsbad, CA). Pancreatic tissue was recovered and subjected to a 12-min digestion at 37degreesC. Subsequently, ice-cold HBSS was added, and the suspension was vortexed at full speed for 10 s. Islets were purified on a discontinuous Ficoll gradient (Sigma) and hand-picked under a dissection microscope. Islets were used immediately after isolation to obtain RNA.
###end p 28
###begin title 29
Evaluation of cellular stress.
###end title 29
###begin p 30
###xml 34 49 <span type="species:ncbi:10090">transgenic mice</span>
To evaluate whether the islets of transgenic mice showed signs of distress, we determined the levels of expression of several "stress genes" by quantitative PCR. Primers used were sarcoendoplasmatic reticulum CA/ATPase type 2, GGCAAGATCCGGGATGAAAT (forward) and TCCAGACTGCAATGCAAATGA (reverse); GADD153/CHOP [CCAAT/enhancer binding protein], TCTCATCCCCAGGAAACGAA (forward) and ATCTGGAGAGCGAGGGCTTT (reverse); XBP-1, CTTTCATCCAGCCATTGTCTGA (forward) and GCCCTCATATCCACAGTCACTGT (reverse); activating transcription factor-4, CGAGTTAAGCACATTCCTGGA (forward) and TTCGCTGTTCAGGAAGCTCAT (reverse); immunoglobulin heavy-chain binding protein, ACCCCGAGAACACGGTCTT (forward) and GCTGCA CCGAAGGGTCATT (reverse); and tumor necrosis factor receptor-associated, AAGATGGAGGCCAAGAATTCC (forward) and AGTCCTGTTAGGTCCACAATAGCTTT (reverse).
###end p 30
###begin p 31
###xml 52 56 <span type="species:ncbi:10090">mice</span>
As positive controls, we used islets from wild-type mice (8 weeks of age) that were treated with a single intraperitoneal injection of streptozotocin (STZ) (250 mg/kg body wt). Eight hours later, islets were isolated as described above.
###end p 31
###begin title 32
Quantitative real-time PCR.
###end title 32
###begin p 33
Total RNA was extracted from pooled islets using the RNeasy maxi kit (Qiagen) according to the manufacturer's instructions. Reverse transcription was performed for 3 mug RNA. Quantitative PCR was conducted in duplicate from 25 ng cDNA and with each primer at 0.4 mumol/l in a 30-mul final reaction volume of 1x SYBR Green PCR Master Mix (Applied Biosystems). PCR cycling conditions were 50degreesC for 2 min, 95degreesC for 15 min, and 40 cycles of 95degreesC for 15 s and 60degreesC for 1 min. Relative expression levels were calculated as 2Ct ubiquitin-Ct gene (where Ct is cycle threshold; for details see ABI PRISM 7700 User Bulletin no. 2; Applied Biosystems) using ubiquitin RNA as endogenous control.
###end p 33
###begin title 34
Protein analysis.
###end title 34
###begin p 35
CCL2 was measured in serum by ELISA (R&D Systems, Minneapolis, MN). Enzyme-linked immunosorbent assay (ELISA) assays were done according to manufacturer's instructions.
###end p 35
###begin title 36
Flow cytometry analysis.
###end title 36
###begin p 37
###xml 597 602 <span type="species:ncbi:10090">mouse</span>
Peripheral blood was stained for 45 min with the antibody mixture, erythrocytes were lysed, and cells were fixed with flow cytometry analysis (FACS) lysis solution (Becton Dickinson, San Jose, CA). Bone marrow cells were obtained from the tibia and femur bones. Contaminating erythrocytes were lysed with ammonium chloride lysis buffer and samples were stained with antibody mixture for 45 min at 4degreesC. Antibodies used in the experiments described here were as follows: anti-CD115 (AFS98), anti-CD11b (M1/70), anti-CD11c (N418), and anti-F4/80 (BM8) from e-Bioscience (San Diego CA) and anti-mouse Ly6C (AL-21) from BD Pharmingen (San Diego, CA). Samples were analyzed in a FACSCanto instrument (Becton Dickinson). Up to 100,000 events were acquired.
###end p 37
###begin p 38
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 836 840 830 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 552 557 <span type="species:ncbi:10090">mouse</span>
Flow cytometry analysis of the bone marrow perfusate was performed as follows: The perfusate was centrifuged (200 x g for 5 min, 4degreesC). Erythrocytes were lysed using hypotonic shock, and the cell pellets were resuspended in FACS buffer. An aliquot of cells was taken to establish the total number of leukocytes mobilized over the 60-min period by staining with 2% methylene blue in 1% acetic acid. Cells were enumerated using an improved Neubauer Hemocytometer. The remaining leukocytes were stained with the following monoclonal antibodies: anti-mouse CD115, Gr1, CD3e, and B220. Appropriately conjugated isotype control antibodies were used to calculate background fluorescence. The samples were then analyzed by flow cytometry (BD FACSCalibur), and the relative number of cells expressing CD115/Gr1 intermediate (monocytes), Gr1high (neutrophils), CD3 (T-lymphocytes), and B220 (B-lymphocytes) was calculated.
###end p 38
###begin title 39
Statistical analysis.
###end title 39
###begin p 40
###xml 63 64 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 164 165 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Data are expressed as means +/- SE. One-way ANOVA and unpaired t test were used to determine statistical significance. Differences were considered significant when P < 0.05.
###end p 40
###begin title 41
RESULTS
###end title 41
###begin title 42
Levels of CCL2 and frequency of mononuclear infiltrates in the islets correlate with development of diabetes.
###end title 42
###begin p 43
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 267 269 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 427 428 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 714 715 711 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 708 715 705 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 718 720 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 966 968 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1617 1618 1614 1615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1611 1618 1608 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 421 425 <span type="species:ncbi:10090">mice</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
###xml 834 838 <span type="species:ncbi:10090">mice</span>
###xml 1158 1162 <span type="species:ncbi:10090">mice</span>
###xml 1260 1264 <span type="species:ncbi:10090">mice</span>
###xml 1271 1286 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1541 1545 <span type="species:ncbi:10090">mice</span>
###xml 1577 1581 <span type="species:ncbi:10090">mice</span>
We have previously described the generation of five transgenic lines expressing different levels of CCL2 in the islets (26). We have observed that the number of inflammatory cells recruited to the islets is dependent on the levels of CCL2 produced by the beta-cells (26). To investigate the frequency of mononuclear infiltration, semiquantitative analysis of infiltrated islets was performed in pancreata from 4-week-old mice (n = 8/group). No infiltrates were found in islets of wild-type mice regardless of age. In marked contrast, 60, 80, 95, and 100% of the islets in RIPCCL2 pancreata from lines 251, 10, 254, and 1, respectively, were infiltrated by leukocytes (largely monocytes and dendritic cells) (Fig. 1A) (26). The infiltrates were observed predominantly in the periphery of the islets in lines 251 and 10. Pancreata from mice of lines 254 and 1 showed a severe insulitis, with leukocytes present in the periphery and within the islets (data not shown) (26). The frequency and the size of these infiltrates did not change with age. To examine whether an increased number of infiltrated islets led to development of diabetes, we monitored RIPCCL2 mice and their control littermates weekly for hyperglycemia. No hyperglycemia was observed in control mice or in transgenic mice of lines 10 and 251 during the first 20 weeks of life. In contrast, animals from lines 254 and 1 (which had higher levels of CCL2 and an increased number of infiltrated islets) became hyperglycemic at 4-5 weeks of age. By 16 weeks of age, 80% of RIPCCL2 mice from line 1 and 60% of RIPCCL2 mice from line 254 were diabetic (Fig. 1B).
###end p 43
###begin p 44
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 425 426 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 929 930 926 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 546 550 <span type="species:ncbi:10090">mice</span>
###xml 790 794 <span type="species:ncbi:10090">mice</span>
###xml 904 908 <span type="species:ncbi:10090">mice</span>
The development of diabetes in several transgenic lines has been linked to toxicity induced by transgene expression (28). To test this, we isolated islets from 6- to 8-week-old wild-type and normoglycemic RIPCCL2 mice and evaluated the expression of genes induced during cellular stress by quantitative PCR. As a positive control, we used islets isolated from wild-type mice injected with STZ. As shown in supplemental Fig. 1A (available in an online appendix at ), islets isolated from mice administered STZ, but not those isolated from RIPCCL2 mice, had increased expression of stress genes. To exclude the possibility that transgene expression of CCL2 by beta-cells led to impaired glucose tolerance, we performed a glucose tolerance test on 8-week-old control and normoglycemic RIPCCL2 mice. The glucose levels after intraperitoneal injection of glucose were comparable between wild-type and RIPCCL2 mice (supplemental Fig. 1B), suggesting that overexpression of CCL2 in the islets did not affect their ability to respond to a glucose challenge. Together, the results indicate that expression of CCL2 per se did not lead to cellular stress or affect the function of the beta-cells. We suggest that the development of diabetes was dependent on the recruitment of myeloid cells by CCL2.
###end p 44
###begin title 45
Levels of CCL2 in the islets and blood correlate with the number of monocytes in circulation.
###end title 45
###begin p 46
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 308 315 308 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 607 608 607 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 601 608 601 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 791 792 791 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 891 892 891 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 906 907 906 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 900 907 900 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
The increased number of monocytes in the islets could be due to increased efficiency in recruitment of a fixed number of circulating cells or to an increased number of monocytes in circulation. To determine whether RIPCCL2 mice had more circulating monocytes, we performed FACS analysis of peripheral blood (Fig. 1C). Blood monocytes were defined as a leukocyte population with low side scatter that expressed the markers CD115, Ly6C, F4/80, and CD11b. Using these parameters, we found that RIPCCL2 mice had higher numbers of monocytes in circulation than control mice (10-30 and 5-6%, respectively) (Fig. 1C). We hypothesized that the increased number of cells in circulation was promoted by CCL2 produced by the islets of the RIPCCL2 mice. Serum from RIPCCL2 animals from different lines (n = 20 in each line, nondiabetic) had 3- to 35-fold more CCL2 than their nontransgenic littermates (n = 20) (Fig. 1D). The levels of CCL2 in serum correlated directly with the amount of CCL2 produced in the transgenic islets (26). These results confirm a correlation between increased levels of CCL2 in the tissue and blood and the number of monocytes in circulation.
###end p 46
###begin title 47
CCL2 induces release of monocytes from the bone marrow.
###end title 47
###begin p 48
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 769 775 769 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 1006 1007 1006 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1000 1007 1000 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 1061 1062 1061 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 1119 1120 1119 1120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 1251 1252 1251 1252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1257 1258 1257 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1273 1274 1273 1274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1293 1294 1293 1294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 147 152 <span type="species:ncbi:10090">mouse</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 462 467 <span type="species:ncbi:10090">mouse</span>
###xml 966 970 <span type="species:ncbi:10090">mice</span>
###xml 994 998 <span type="species:ncbi:10090">mice</span>
To determine whether CCL2 could exert a direct effect on the release of monocytes from the bone marrow, we used an in situ perfusion system of the mouse femoral bone marrow (29). The femoral artery and vein were cannulated in situ such that the femoral bone marrow could be perfused and the leukocytes released from the bone marrow collected as they exited via the femoral vein. Vehicle alone (PBS, control mice) or CCL2 was infused for 20 min directly into the mouse femoral artery using a Minipuls peristaltic pump, and the leukocytes mobilized from the femoral bone marrow were collected over a subsequent 60-min perfusion period. The numbers of monocytes, neutrophils, T-cells, and B-cells released into the perfusate were determined by flow cytometry. As shown in Fig. 2, CCL2 induced an increased release of monocytes from the bone marrow over the 60-min perfusion period compared with controls. The relative number of monocytes changed from 6% in PBS-infused mice to 13% in CCL2-infused mice (Fig. 2B). Moreover, CCL2 induced bone marrow release of 7 x105 monocytes/ml perfusate, whereas PBS controls had 2.5 x105 monocytes/ml perfusate. However, CCL2 infusion did not result in significant changes in the relative numbers of neutrophils (CD115-/GR-1+), T-cells (CD3+), or B-cells (B220+) (data not shown). These results support the hypothesis that an increased concentration of CCL2 in circulation can induce monocyte release from the bone marrow.
###end p 48
###begin title 49
CCL2 promotes monocyte release from the bone marrow via CCR2.
###end title 49
###begin p 50
###xml 257 260 257 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 349 350 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 355 356 355 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 368 375 368 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 756 759 756 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 793 794 793 794 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 799 800 799 800 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 828 831 828 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 844 845 844 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 838 845 838 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 998 999 998 999 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1031 1034 1031 1034 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1064 1067 1064 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 1080 1081 1080 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1074 1081 1074 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 1134 1135 1134 1135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1155 1158 1155 1158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1372 1374 1372 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 1375 1377 1375 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 1404 1407 1404 1407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1461 1462 1461 1462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 453 457 <span type="species:ncbi:10090">mice</span>
###xml 513 517 <span type="species:ncbi:10090">mice</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
###xml 719 723 <span type="species:ncbi:10090">mice</span>
###xml 760 764 <span type="species:ncbi:10090">mice</span>
###xml 832 836 <span type="species:ncbi:10090">mice</span>
###xml 1035 1039 <span type="species:ncbi:10090">mice</span>
###xml 1068 1072 <span type="species:ncbi:10090">mice</span>
###xml 1159 1163 <span type="species:ncbi:10090">mice</span>
###xml 1246 1250 <span type="species:ncbi:10090">mice</span>
###xml 1408 1412 <span type="species:ncbi:10090">mice</span>
CCL2 is the ligand for the chemokine receptor CCR2. To demonstrate a tight link between the monocytosis in the RIPPCCL2 mice and the production of CCL2 in the periphery, we crossed RIPCCL2 mice (line 254) with CCR2-deficient animals to generate RIPCCL2/CCR2-/- mice. Deletion of CCR2 led to a significant decrease in the circulating numbers of CD115+/Ly6C+ monocytes (Fig. 3A), consistent with previous results (30). Genetic deletion of CCR2 in RIPCCL2 mice completely abrogated the monocytosis observed in these mice. FACS analysis of bone marrow showed that the number of monocytes in the bone marrow of wild-type mice varies between 5 and 9%. Similar numbers of monocytes were obtained in the bone marrow of RIPCCL2 mice. On the other hand, RIPCCL2/CCR2-/- mice had a larger number of CD115+/Ly6c+ monocytes than RIPCCL2/CCR2+/- mice (Fig. 3B). Analysis of islets infiltrates by immunostaining with anti-CD45 and anti-insulin showed that deletion of CCR2 significantly reduced the number of CD45+ cells in islets of RIPCCL2/CCR2-/- mice relative to RIPCCL2/CCR2+/- mice (Fig. 3C). Despite the marked reduction in the number of CD45+ cells, RIPCCL2/CCR2-/- mice still showed higher numbers of leukocytes in the pancreatic islets than wild-type mice, suggesting that leukocytes could still migrate to CCL2-expressing tissue in the absence of CCR2 as suggested by others (30,31). None of the RIPCCL2/CCR2-/- mice analyzed developed diabetes by 16 weeks of age (n = 30). These results indicate that CCR2 is required for effective mobilization of monocytes from the bone marrow in response to systemically elevated levels of CCL2.
###end p 50
###begin title 51
###xml 71 75 <span type="species:ncbi:10090">mice</span>
Modulation of the number of circulating monocytes promotes diabetes in mice expressing low levels of CCL2 in the islets.
###end title 51
###begin p 52
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 369 370 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 363 370 363 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 795 796 795 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 789 796 789 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 826 827 826 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 932 933 932 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 939 940 939 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 971 972 971 972 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1138 1139 1138 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1132 1139 1132 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 1150 1151 1150 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1157 1158 1157 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 662 666 <span type="species:ncbi:10090">mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 868 872 <span type="species:ncbi:10090">mice</span>
###xml 895 899 <span type="species:ncbi:10090">mice</span>
###xml 903 907 <span type="species:ncbi:10090">mice</span>
###xml 1088 1092 <span type="species:ncbi:10090">mice</span>
One of the predictions of the previous studies was that an increased number of circulating monocytes could lead to diabetes development if CCL2 was expressed in the islets. To test this hypothesis, we crossed RIPCCL2 mice from lines 251 and 10 with animals that conditionally express the myeloid growth factor Flt3L upon administration of doxycycline (DOX) (32) (Fig. 4A). Flt3L is a known growth factor for pluripotent hemopoietic stem cells and progenitor cells (33). Flt3L is also reported to increase numbers of lymphocytes, granulocytes, and monocytes in peripheral blood (34,35). Animals with the CCL2 and Flt3L transgenes are referred to as RIPCCL2/Flt3L mice. First, we analyzed the peripheral blood from untreated and treated RIPCCL2/Flt3L mice from lines 251 and 10. As shown in Fig. 4B, the relative number of CD115+ monocytes changed from 10% in untreated mice to 28% in DOX-treated mice in mice from line 251 (unpaired t test P < 0.0001). Evaluation of CD115+ monocytes in blood also showed an increase in the relative number of those cells from 16 to 35% when RIPCCL2/Flt3L mice from line 10 were treated for 2 weeks (Fig. 4C; unpaired t test P < 0.0001).
###end p 52
###begin p 53
###xml 453 454 453 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 447 454 447 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 475 476 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 469 476 469 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>E</italic></xref>
###xml 734 735 734 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 728 735 728 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>F</italic></xref>
###xml 740 741 740 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 977 978 977 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 971 978 971 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>H</italic></xref>
###xml 1238 1239 1238 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1232 1239 1232 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>H</italic></xref>
###xml 1360 1361 1360 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1354 1361 1354 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>I</italic></xref>
###xml 1470 1471 1470 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1464 1471 1464 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>I</italic></xref>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 258 273 <span type="species:ncbi:10090">transgenic mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
###xml 689 704 <span type="species:ncbi:10090">transgenic mice</span>
###xml 813 817 <span type="species:ncbi:10090">mice</span>
###xml 917 921 <span type="species:ncbi:10090">mice</span>
###xml 1033 1037 <span type="species:ncbi:10090">mice</span>
###xml 1288 1292 <span type="species:ncbi:10090">mice</span>
###xml 1400 1404 <span type="species:ncbi:10090">mice</span>
###xml 1422 1426 <span type="species:ncbi:10090">mice</span>
###xml 1546 1550 <span type="species:ncbi:10090">mice</span>
Because the circulating monocyte population increased, we then determined whether islets from DOX-treated mice would show increased mononuclear cell infiltration. We examined histological sections of pancreata from untreated (-DOX) and treated (+DOX) double transgenic mice from both lines. Immunostaining with antibodies against CD45 and insulin showed infiltrates of varying sizes in islets of untreated (-DOX) RIPCCL2/Flt3L mice from line 251 (Fig. 4D) and line 10 (Fig. 4E), similar to what was observed in pancreata from RIPCCL2 animals of each line. In striking contrast, DOX treatment of RIPCCL2/Flt3L mice led to an increased number of leukocytes infiltrating the islets of double-transgenic mice from lines 251 and 10 (Fig. 4F and G, respectively). Subsequently, DOX-untreated and -treated RIPCCL2/Flt3L mice were monitored weekly for onset of hyperglycemia. As expected, none of the untreated RIPCCL2/Flt3L mice from line 251 developed diabetes after 10 weeks (Fig. 4H). However, 5 weeks after DOX treatment, RIPCCL2/Flt3L mice from line 251 started to show diabetes (70% of the animals in this group were diabetic after 10 weeks of treatment). No disease was observed in DOX-treated Flt3L littermates during this period (Fig. 4H). Strikingly, 100% of DOX-treated RIPCCL2/Flt3L mice from line 10 developed diabetes 14 days after DOX treatment (Fig. 4I). None of the untreated RIPCCL2/Flt3L mice or treated Flt3L mice developed diabetes during this time (Fig. 4I). Together, these results suggest that development of diabetes in RIPCCL2 mice depended both on the levels of expression of CCL2 in the islets and on the number of circulating cells.
###end p 53
###begin title 54
###xml 35 39 <span type="species:ncbi:10090">mice</span>
Development of diabetes in RIPCCL2 mice does not depend on T- and B-cells.
###end title 54
###begin p 55
###xml 416 419 413 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 483 486 480 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 504 507 501 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 555 558 552 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 625 628 622 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 734 735 731 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5</italic>
###xml 729 735 726 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. <italic>5</italic></xref>
###xml 758 761 755 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 888 891 885 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 629 633 <span type="species:ncbi:10090">mice</span>
###xml 762 766 <span type="species:ncbi:10090">mice</span>
###xml 892 896 <span type="species:ncbi:10090">mice</span>
Because type 1 diabetes is a Th1-mediated autoimmune process induced by activated diabetogenic T-cells, the increase in the myeloid cells in the tissue could favor priming of T-cells or could itself lead to beta-cell destruction. To investigate whether T- and B-cells were required to induce diabetes in RIPCCL2 mice, we crossed RIPCCL2 mice from line 1 (a line that develops diabetes with high incidence) with Rag-1-/- mice, which lack mature T- and B-cells, to generate RIPCCL2/Rag-/- mice. RIPCCL2/Rag-/- mice and their control littermates (RIPCCL2/Rag+/-) were monitored weekly for hyperglycemia. As expected, RIPCCL2/Rag+/- mice started to develop diabetes by 6 weeks of age and reached 60% of incidence by 30 weeks of age (Fig. 5). Although RIPCCL2/Rag-/- mice developed diabetes with a similar course, the incidence of diabetes was significantly increased compared with RIPCCL2/Rag+/- mice. This result suggests that mature T- and B-cells are not necessary for diabetes in this model, which is dependent primarily on myeloid cells to induce disease.
###end p 55
###begin title 56
DISCUSSION
###end title 56
###begin p 57
###xml 176 178 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
Type 1 diabetes is an autoimmune disease characterized by a local inflammatory reaction in and around islets followed by selective destruction of insulin-secreting beta-cells (36). Here, we show that accumulation of monocytes in islets of Langerhans is sufficient for induction of type 1 diabetes. In the model that we have developed, monocytes accumulate in the islet because of expression in the beta-cells of the chemokine CCL2, which acts both locally and remotely to promote monocyte influx.
###end p 57
###begin p 58
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 1353 1355 1353 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 965 969 <span type="species:ncbi:10090">mice</span>
###xml 1240 1244 <span type="species:ncbi:10090">mice</span>
While local chemotactic activity has been demonstrated previously, only recently have chemokines been shown to modulate release of cells from the bone marrow (29,37). For instance, the chemokines CCL11 and CXCL1 have been shown to selectively mobilize eosinophils and neutrophils from the bone marrow, respectively (29,37). Mobilization of monocytes from the bone marrow is controlled mainly by CCR2 (30,31). During inflammation it has been suggested that CCL2 may be involved in this process (30), but the absence of a reductionist model has precluded firm conclusions. Here, we have directly tested the hypothesis that CCL2 can mobilize cells from the marrow in a transgenic model in which this chemokine is overexpressed in a single site (islets of Langerhans). We show a direct correlation between circulating numbers of monocytes and levels of CCL2 in tissue and in the blood. Furthermore, we show that infusion of CCL2 into the femoral bone marrow of control mice leads to monocyte mobilization from the femoral bone marrow into the bloodstream, strongly suggesting that the main mechanism accounting for the monocytosis is the direct release of monocytes from the bone marrow. The fact that deletion of CCL2 receptor CCR2 in RIPCCL2 mice abrogated monocytosis further supports an important role for CCR2 in monocyte release from the bone marrow (30).
###end p 58
###begin p 59
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 679 680 679 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 824 826 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 911 912 899 900 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 982 984 970 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 248 251 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 549 557 <span type="species:ncbi:9606">patients</span>
###xml 714 718 <span type="species:ncbi:10090">mice</span>
###xml 728 734 <span type="species:ncbi:9606">humans</span>
###xml 877 881 <span type="species:ncbi:10090">mice</span>
There are several inflammatory conditions in which CCL2 serum levels correlate with pathogenesis and/or disease activity, including ischemic stroke and myocardial infarction (38), rheumatoid arthritis (39), chronic autoimmune thyroiditis (40), and HIV (41). Although many of these studies suggest that CCL2 serum levels could serve as a parameter to monitor the stage and severity of the disease, correlations between CCL2 serum levels, the number of monocytes in circulation, and the extent of mononuclear cell infiltration in the tissues in these patients have not been analyzed. However, a positive correlation between plasma levels of CCL2 and the number of circulating CD11b+ cells has been observed in obese mice (42). In humans, the number of monocytes increases by approximately10% in obese and overweight subjects (43). Furthermore, systemic administration of CCL2 in mice causes accumulation of MOMA-2+ monocytes in collateral arteries and increases neointimal formation (44). These observations strongly suggest that changes in plasma levels of CCL2 may lead to changes in the number of monocytes in circulation and that both of these parameters are indexes of disease severity.
###end p 59
###begin p 60
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 813 817 <span type="species:ncbi:10090">mice</span>
The mechanisms accounting for monocyte accumulation in chronically inflamed tissues are not completely understood. We propose that one of the factors contributing to this process is CCL2. In this study, we show that CCL2 can induce recruitment of monocytes to the islets and that the number of infiltrated islets depends on CCL2 concentration and monocyte availability. These findings may have relevance in the context of diabetes because they suggest a direct role for these cells in the process of islet destruction. Indirect evidence suggests such a role. For example, inhibition of macrophage infiltration by silica treatment abolishes lymphocytic insulitis and diabetes development in the model featuring multiple low doses of STZ (MLDS) (45). Diabetes in the MLDS model can also be induced in NOD scid/scid mice lacking functional lymphocytes (46), which offers evidence for the importance of monocytes.
###end p 60
###begin p 61
###xml 281 284 281 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 334 337 334 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 411 414 411 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 524 527 524 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 1446 1448 1440 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 285 289 <span type="species:ncbi:10090">mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 761 767 <span type="species:ncbi:9606">humans</span>
###xml 823 831 <span type="species:ncbi:9606">patients</span>
###xml 1677 1692 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1752 1756 <span type="species:ncbi:10090">mice</span>
###xml 1775 1779 <span type="species:ncbi:10090">mice</span>
###xml 1915 1919 <span type="species:ncbi:10090">mice</span>
Although the preponderance of the evidence points to a critical importance of T-cells in the pathogenesis of type 1 diabetes, we show here that damage to the islets can be directly caused by monocytes and dendritic cells. Interestingly, the incidence of diabetes in the RIPCCL2/Rag-/- mice was actually higher than that in RIPCCL2/Rag+/- mice. The reasons for the higher incidence of diabetes in the RIPCCL2/Rag-/- group are not clear, but an intrinsic augmented activity of monocytes or other innate immune cells in the Rag-/- background may be reflected. In type 1 diabetes, an initial attack by monocytes and dendritic cells may put in motion a cascade of events leading to expansion of an autoreactive T-cell pool and complete destruction of the islets. In humans, circulating monocytes from type 1 and type 2 diabetic patients show an aberrant cytokine profile when stimulated (47), suggesting that they may contribute to the initiation or continuation of an immune attack against the pancreatic beta-cells. We suggest that T-cells and macrophages may synergize to mediate islet pathology. Although our results suggest a key role for monocytes in the development of diabetes, an alternative explanation for our findings might be that the transgenic expression of CCL2 was itself toxic to the islets. Arguing against this hypothesis is the finding that expression of several transcription factors associated with beta-cell apoptosis (rev. in 48) did not differ in transgenic or control islets, suggesting that CCL2 expression did not induce stress in the islets. Furthermore, transgenic expression of CCL2 did not impair glucose homeostasis. Before development of disease, transgenic mice responded to a glucose tolerance test similarly to control mice. Finally, RIPCCL2 mice lacking CCR2 did not develop diabetes over time, which rules out a direct toxic effect of CCL2 as the cause of diabetes in the RIPCCL2 mice.
###end p 61
###begin p 62
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
We propose that the local concentration of CCL2 and the number of circulating monocytes play an important role in the onset of autoimmune diseases. Our group has shown that expression of CCL2 in the central nervous system drives monocyte/macrophage accumulation in the central nervous system without any symptom of neurological disease (49). However, those mice develop a severe demyelinating encephalomyelitis if the numbers of monocytes/macrophages and dendritic cells are altered in the periphery (34). Here, we show that elevating the number of monocytes by transgenic expression of Flt3L in RIPCCL2 lines with lower expression of CCL2 (RIPCCL2/Flt3L mice) results in increased monocyte infiltration of the islets and diabetes.
###end p 62
###begin p 63
###xml 364 379 <span type="species:ncbi:10090">transgenic mice</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
###xml 454 460 <span type="species:ncbi:9606">humans</span>
In summary, we find that the ability of CCL2 to promote tissue-specific influx of monocytes is due to two factors: its capacity to trigger mobilization of monocytes from bone marrow into circulation and its ability to mediate influx of monocytes into tissues. These properties are key for the infiltration and subsequent destruction of the islets of Langerhans in transgenic mice. The relevance of these mechanisms for autoimmune disease in NOD mice and humans is currently under investigation.
###end p 63
###begin title 64
Supplementary Material
###end title 64
###begin title 65
Online-Only Appendix
###end title 65
###begin p 66
S.A.L. has received National Institutes of Health Grant DK-067381. G.C.F. has received the Dana Foundation Grant. S.P. has received British Heart Foundation Grant PG/05/-92.
###end p 66
###begin p 67
We thank Peter Heeger, Bernd Schroppel, Miriam Merad, and Jay Unkeless for comments and suggestions to the manuscript and Claudia Canasto-Chibuque for expert technical assistance.
###end p 67
###begin title 68
REFERENCES
###end title 68
###begin p 69
###xml 146 147 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 273 274 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 287 288 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 354 355 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 367 368 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 441 442 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 450 451 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 478 479 478 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 528 529 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 554 555 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 563 564 563 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 577 578 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 590 591 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 712 713 712 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 725 726 725 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 734 735 734 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 748 749 748 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 238 253 <span type="species:ncbi:10090">transgenic mice</span>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
###xml 522 526 <span type="species:ncbi:10090">mice</span>
###xml 535 539 <span type="species:ncbi:10090">mice</span>
###xml 629 633 <span type="species:ncbi:10090">mice</span>
Augmented levels of CCL2 in islets of Langerhans lead to an increased number of monocytes in blood, infiltrated islets, and spontaneous diabetes. A: Semiquantitative analysis of islet infiltrates in the pancreata from control and RIPCCL2 transgenic mice at 4 weeks of age (n = 8/group). B: Cumulative incidence of diabetes in RIPCL2 mice from lines 251 (n = 60), 10 (n = 40), 254 (n = 95), and 1 (n = 31) and from nontransgenic littermates (n = 20). C: Relative numbers of CD115+ cells in blood from wild-type and RIPCCL2 mice (n = 20 mice in each line; t test **P < 0.005, ***P < 0.0001). D: CCL2 levels in the serum of RIPCCL2 mice of lines 251, 10, 254, and 1 and wild-type littermates was analyzed by ELISA (n = 20/line; t test **P < 0.005, ***P < 0.0001).
###end p 69
###begin p 70
###xml 123 150 123 150 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 152 153 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 243 244 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 308 309 308 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 314 326 314 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">intermediate</sup>
###xml 373 374 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 403 404 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 411 412 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 423 424 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 379 383 <span type="species:ncbi:10090">mice</span>
CCL2 induces release of monocytes from the bone marrow. The perfusion of femoral bone marrow was performed as described in research design and methods. A: Representative dot plot of monocyte release from bone marrow induced by CCL2 perfusion. B and C: Relative (B) and absolute (C) number of monocytes (CD115+/Gr-1intermediate cells) after PBS (control) or CCL2 perfusion (n = 5 mice in each treatment; t test *P < 0.05, **P < 0.005).
###end p 70
###begin p 71
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 100 101 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 172 175 172 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 189 192 189 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 210 213 210 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 272 273 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 287 288 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 383 386 383 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 404 407 404 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 251 256 <span type="species:ncbi:10090">mouse</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
Deletion of CCR2 abrogates peripheral monocytosis in RIPCCL2 mice. A and B: Relative number of CD115+Ly6C+ monocytes in the blood (A) and bone marrow (B) of wild-type, CCR2-/-, RIPCCL2/CCR2+/-, and RIPCCL2/CCR2-/- mice. Data are representative of one mouse in each group (n = 10/group). C: Immunostaining for CD45 (red) and insulin (green) in the pancreata of wild-type, RIPCCL2/CCR2+/-, and RIPCCL2/CCR2-/- mice at 8 weeks of age. Scale bars = 100 mum. (Please see  for a high-quality digital representation of this figure.)
###end p 71
###begin p 72
###xml 125 126 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 269 272 269 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 878 879 866 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 906 907 894 895 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 978 979 966 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1017 1018 1005 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1045 1046 1033 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1054 1055 1042 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1082 1083 1070 1071 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1154 1155 1142 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1193 1194 1181 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1220 1221 1208 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1229 1230 1217 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1231 1232 1219 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1321 1322 1309 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1327 1328 1315 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1348 1349 1336 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1354 1355 1342 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1391 1392 1379 1380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1397 1398 1385 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1412 1413 1400 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1418 1419 1406 1407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1422 1423 1410 1411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1511 1512 1499 1500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1544 1545 1532 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1577 1578 1565 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1686 1687 1674 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1775 1776 1763 1764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1808 1809 1796 1797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1841 1842 1829 1830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 279 300 <span type="species:ncbi:10359">human cytomegalovirus</span>
###xml 340 347 <span type="species:ncbi:9031">chicken</span>
###xml 720 723 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 733 736 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 758 764 <span type="species:ncbi:9986">rabbit</span>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
###xml 837 841 <span type="species:ncbi:10090">mice</span>
###xml 872 876 <span type="species:ncbi:10090">mice</span>
###xml 952 956 <span type="species:ncbi:10090">mice</span>
###xml 1025 1029 <span type="species:ncbi:10090">mice</span>
###xml 1128 1132 <span type="species:ncbi:10090">mice</span>
###xml 1201 1205 <span type="species:ncbi:10090">mice</span>
###xml 1371 1375 <span type="species:ncbi:10090">mice</span>
###xml 1485 1489 <span type="species:ncbi:10090">mice</span>
###xml 1538 1542 <span type="species:ncbi:10090">mice</span>
###xml 1571 1575 <span type="species:ncbi:10090">mice</span>
###xml 1636 1640 <span type="species:ncbi:10090">mice</span>
###xml 1749 1753 <span type="species:ncbi:10090">mice</span>
###xml 1802 1806 <span type="species:ncbi:10090">mice</span>
###xml 1835 1839 <span type="species:ncbi:10090">mice</span>
###xml 1899 1903 <span type="species:ncbi:10090">mice</span>
Increased availability of circulating monocytes promotes spontaneous diabetes in RIPCCL2 mice with lower production of CCL2. A: Outline of the RIPCCL2 transgene and of the activator and responder transgenes in the Flt3L mice. In Flt3L mice, in the activator transgene (top), the human cytomegalovirus enhancer (hCMVe) was juxtaposed to the chicken beta-actin promoter to control the expression of reverse tetracycline-controlled transactivator. The responder transgene encodes beta-galactosidase and mFlt3L in opposite orientation. Transcription of the beta-galactosidase and mFlt3L genes is strongly induced when DOX and reverse tetracycline-controlled transactivator are present. TRE, tetracycline-responsive element; CMV, minimal CMV promoter; and rglob, rabbit beta-globin. RIPCCL2 mice from lines 251 and 10 were crossed with Flt3L mice to generate the RIPCCL2/Flt3L mice. B: Relative numbers of CD115+ cells in blood from untreated RIPCCL2/Flt3L mice (RIPCCL2/Flt3L -DOX, n = 13) and DOX-treated RIPCCL2/Flt3L (n = 21) mice from line 251 (t test). C: Relative numbers of CD115+ cells in blood from untreated RIPCCL2/Flt3L mice (RIPCCL2/Flt3L -DOX, n = 15) and DOX-treated RIPCCL2/Flt3L (n = 11) mice from line 10 (t test). D-G: Immunostaining for CD45 (red) and insulin (green) in the pancreata of untreated (-DOX; D and E) or treated (+DOX; F and G) RIPCCL2/Flt3L mice from line 251 (D and F) or line 10 (E and G). H: Cumulative incidence of diabetes in untreated RIPCCL2/Flt3L mice (RIPCCL2/Flt3L -DOX, n = 13), DOX-treated Flt3L mice (n = 10), and RIPCCL2/Flt3L mice (n = 21) from line 251. Note that DOX-treated RIPCCL2/Flt3L mice developed diabetes after weeks of treatment. I: Cumulative incidence of diabetes in untreated RIPCCL2/Flt3L mice (RIPCCL2/Flt3L -DOX, n = 15), DOX-treated Flt3L mice (n = 10), and RIPCCL2/Flt3L mice (n = 29) from line 10. Note that DOX-treated RIPCCL2/Flt3L mice developed diabetes after days of treatment. Scale bars = 100 mum. (Please see  for a high-quality digital representation of this figure.)
###end p 72
###begin p 73
###xml 106 109 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 133 136 133 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 138 139 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 171 172 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 20 24 <span type="species:ncbi:10090">mice</span>
Diabetes in RIPCCL2 mice does not depend on T- and B-cells. Cumulative incidence of diabetes in RIPCL2/Rag+/- (n = 12) and RIPCL2/Rag-/- (n = 28) littermates from line 1 (P = 0.007).
###end p 73

